NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Sun Pharma Advanced Research Company Limited (NSE: SPARC)

 
SPARC Technical Analysis
1.5
As on 18th Apr 2024 SPARC SHARE Price closed @ 350.05 and we RECOMMEND Buy for LONG-TERM with Stoploss of 113.99 & Sell for SHORT-TERM with Stoploss of 364.54 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

SPARCSHARE Price

Open 350.05 Change Price %
High 350.05 1 Day -18.40 -4.99
Low 350.05 1 Week -79.65 -18.54
Close 350.05 1 Month -12.95 -3.57
Volume 83387 1 Year 232.55 197.91
52 Week High 455.30 | 52 Week Low 110.25
 
NSE INDIA Most Active Stocks
IDEA 13.20 1.93%
YESBANK 23.90 -0.21%
TATASTEEL 160.05 0.00%
POWERGRID 280.10 2.13%
DHANI 51.45 7.19%
NHPC 89.50 -1.86%
EXIDEIND 449.65 -2.21%
GTLINFRA 1.75 2.94%
INDUSTOWER 344.40 3.58%
PNB 129.55 0.78%
 
NSE INDIA Top Gainers Stocks
KMSUGAR 36.05 19.97%
JUSTDIAL 1009.35 13.27%
ORICONENT 43.40 12.87%
SOLARA 473.80 11.97%
TPLPLASTEH 84.25 11.29%
ELIN 164.05 10.58%
ELIN 164.05 10.58%
DSSL 1248.65 10.31%
INDOTECH 1575.40 10.00%
ESSARSHPNG 31.35 10.00%
 
NSE INDIA Top Losers Stocks
STLTECH 129.95 -8.65%
SADBHAV 29.55 -8.51%
COFFEEDAY 64.70 -7.70%
BHAGERIA 172.70 -6.88%
GODHA 0.70 -6.67%
HINDMOTORS 20.50 -6.61%
TIRUPATIFL 17.90 -6.04%
GAYAHWS 0.85 -5.56%
IGL 437.30 -5.49%
IGL 437.30 -5.49%
 
 
SPARC
Daily Charts
SPARC
Intraday Charts
Whats New @
Bazaartrend
SPARC
Free Analysis
 
SPARC Important Levels Intraday
RESISTANCE350.05
RESISTANCE350.05
RESISTANCE350.05
RESISTANCE350.05
RESISTANCE350.05
RESISTANCE350.05
RESISTANCE350.05
RESISTANCE350.05
 
SPARC Target April 2024
4th UP Target922.54
3rd UP Target748.48
2nd UP Target640.89
1st UP Target533.3
1st DOWN Target226.3
2nd DOWN Target118.71
3rd DOWN Target11.12
4th DOWN Target-162.94
 
SPARC Weekly Target
4th UP Target556.24
3rd UP Target508.78
2nd UP Target479.44
1st UP Target450.11
1st DOWN Target366.39
2nd DOWN Target337.06
3rd DOWN Target307.72
4th DOWN Target260.26
 
SPARC Target2024
4th UP Target214.91
3rd UP Target183.67
2nd UP Target164.36
1st UP Target145.05
1st DOWN Target89.95
2nd DOWN Target70.64
3rd DOWN Target51.33
4th DOWN Target20.09
 
 
SPARC Synopsis Technicals View
50 Day EMA Close is Above EMA 50 (Short Term)
Bullish
100 Day EMA Close is Above EMA 100 (Mid Term) Bullish
200 Day EMA Close is Above EMA 200 (Long Term) Bullish
MACD (12 26 9) MACD Line is Less Then SIGNAL Line Bearish
RSI (14) RSI is Below 30 Over Sold
MFI (14) MFI is 45.67 Sideways
CCI (20) CCI is Below -100 Over Sold
WILLIAM %R (14) William %R is Below -80 Over Sold
ADX (14) ADX is Above 20 & +DI is Below -DI Down Trend
PSAR Stoploss For Long Buy 144.76
10 Day Avg Volume Traded -47.32 % Less then 10 Day Average Volume
 
SPARC Other Details
Segment EQ
Market Capital 74794024960.00
Sector Healthcare
Industry Drug Manufacturers-Specialty & Generic
Offical website >
 
SPARC Address
SPARC
 
SPARC Latest News
 
Your Comments and Response on Sun Pharma Advanced Research Company Limited
 
SPARC Business Profile
Sun Pharma Advanced Research Company Limited, a biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops new chemical and biological entities, and reformulated products with a therapeutic focus on oncology, neurodegeneration, ophthalmology, and dermatology. The company offers Elepsia, a formulation of levetiracetam that is an anti-epileptic agent to treat epilepsy disorder; and Xelpros, a latanoprost ophthalmic emulsion for the treatment of open-angle glaucoma or ocular hypertension. In addition, it is developing SDN-037, a formulation of difluprednate for the treatment of inflammation and pain associated with ocular surgery that is in phase 3 clinical trial; PDP-716 to treat glaucoma, which is in phase 3 clinical trial; phenobarbital sodium for the treatment of neonatal seizures; Vodobatinib (SCO-088) for the treatment of resistant chronic myelogenous leukemia that has completed a part A of the Phase 1 study; Vodobatinib (SCC-138), which is in phase 2 clinical trial to treat Parkinson's disease; SCD-044 for the treatment of psoriasis and atopic dermatitis that is in phase 2 clinical trial; and SCO-120 for the treatment of hormone receptor-positive, human epidermal receptor 2 negative, and metastatic breast cancer, which is in phase 1 clinical trial. Sun Pharma Advanced Research Company Limited has a collaboration agreement with Bioprojet SCR to develop an S1P receptor 1 agonist for autoimmune disorders; and HitGen Ltd. to identify small molecule leads for targets of interest. The company was incorporated in 2006 and is based in Mumbai, India. Sun Pharma Advanced Research Company Limited is a subsidiary of Shanghvi Finance Private Limited Address: 17-B, Mahal Industrial Estate, Mumbai, India, 400093
 
© 2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service